Related Experiment Video
Updated: Apr 23, 2026
A Mouse Model for Laser-induced Choroidal Neovascularization
Published on: December 27, 2015
Effect of chromogranin A-derived vasostatin-1 on laser-induced choroidal neovascularization in the mouse
Silvia Maestroni1, Anna Maestroni, Simona Ceglia
1Complications of Diabetes Unit, Division of Metabolic and Cardiovascular Sciences, San Raffaele Scientific Institute, Milan, Italy.
Purpose:
To verify the effect of vasostatin-1 (VS-1), an anti-angiogenic fragment of chromogranin A, in the prevention of choroidal neovascularization (CNV) in an established mouse model of laser-induced ocular neovascularization.
Methods:
Bruch's membrane, the innermost layer of the choroid, was broken by laser photocoagulation in C57/Bl6 mice, to induce CNV. Mice were then treated daily for 14 days by intraperitoneal injection of VS-1 or vehicle (6 mice/group). CNV and vascular leakage were measured at three time-points (day 0, 7 and 14) in vivo by spectral domain optical coherence tomography (OCT) and fluorescein angiography (FA). Ex vivo analysis of CNV was also performed at day 14 by confocal microscopy analysis of dextran-perfused choroidal flat-mounts.
Results:
In vivo analyses showed that VS-1 significantly reduced CNV at day 14 (p = 0.03) and vascular leakage at day 7 (p = 0.01) and 14 (p = 0.04). Ex vivo confocal microscopy analysis of CNV performed on dextran-perfused choroidal flat-mounts at day 14 confirmed the protective activity of VS-1 (p = 0.01). A significant correlation between the results of in vivo and ex vivo analyses of CNV was also observed (p = 0.001, R(2) = 0.81).
Conclusion:
The results indicate that VS-1 can prevent CNV and vascular leakage in a mouse model of ocular neovascularization, suggesting that this polypeptide might have therapeutic activity in human ocular diseases that are complicated by neovascularization or excessive vascular permeability.
Insights
Vasostatin-1 (VS-1) effectively prevents choroidal neovascularization (CNV) and vascular leakage in a mouse model. This anti-angiogenic peptide shows therapeutic potential for human ocular diseases involving neovascularization.
Area of Science:
- Ophthalmology
- Angiogenesis Research
- Molecular Biology
Background:
- Choroidal neovascularization (CNV) is a major cause of vision loss.
- Anti-angiogenic therapies are crucial for treating neovascular eye diseases.
- Vasostatin-1 (VS-1), a fragment of chromogranin A, exhibits anti-angiogenic properties.
Purpose of the Study:
- To evaluate the efficacy of VS-1 in preventing laser-induced CNV in a mouse model.
- To assess the impact of VS-1 on vascular leakage in ocular neovascularization.
Main Methods:
- CNV was induced in C57/Bl6 mice via laser photocoagulation.
- Mice received daily intraperitoneal injections of VS-1 or vehicle for 14 days.
- CNV and vascular leakage were assessed using spectral domain optical coherence tomography (OCT), fluorescein angiography (FA), and ex vivo confocal microscopy.
Main Results:
- VS-1 significantly reduced CNV at day 14 (p = 0.03).
- VS-1 significantly decreased vascular leakage at days 7 (p = 0.01) and 14 (p = 0.04).
- Ex vivo analysis confirmed VS-1's protective effect on CNV (p = 0.01), correlating well with in vivo findings (R² = 0.81).
Conclusions:
- VS-1 demonstrates significant preventive effects against CNV and vascular leakage in a preclinical model.
- These findings suggest VS-1 holds therapeutic promise for human ocular neovascular diseases.
- VS-1 may be a viable treatment option for conditions characterized by aberrant blood vessel growth or permeability.
More Related Videos
09:56In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
Published on: January 21, 2018
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023